

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/743,687	12/19/2003	Jeffrey A. Hubbell	158264-0003	7788
32256	7590 03/07/2006		EXAMINER	
REED SMITH LLP			SZEKELY, PETER A	
1301 K STR	•		ART UNIT	PAPER NUMBER
SUITE 1100 EAST TOWER			ARTONII	PAPER NUMBER
WASHINGTON, DC 20005			1714	
				_

DATE MAILED: 03/07/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		10/743,687	HUBBELL ET AL.		
		Examiner	Art Unit		
		Peter Szekely	1714		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SH WHIC - Exter after - If NC - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATES and the may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
 Responsive to communication(s) filed on <u>17 January 2006</u>. This action is FINAL. 2b) This action is non-final. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11, 453 O.G. 213. 					
Dispositi	on of Claims				
5)□ 6)⊠ 7)□ 8)□ Applicati 9)□ 10)⊠	Claim(s) 19 and 37 is/are pending in the applicated of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 19 and 37 is/are rejected. Claim(s) is/are objected to. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or on Papers The specification is objected to by the Examiner The drawing(s) filed on 19 December 2003 is/are Applicant may not request that any objection to the confidence of the confidence of the oath or declaration is objected to by the Examiner The oath or declaration is objected to by the Examiner Confidence of the	vn from consideration. relection requirement. r. re: a)⊠ accepted or b)□ object drawing(s) be held in abeyance. See on is required if the drawing(s) is object	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority u	ınder 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
2) 🔲 Notice 3) 🔲 Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:			

U.S. Patent and Trademark Office PTOL-326 (Rev. 7-05) Application/Control Number: 10/743,687 Page 2

Art Unit: 1714

DETAILED ACTION

Priority

1. Applicants claim for priority going back to 1992 is denied. Applicants' claim 19 and new claim 37 encompass all ionically and covalently crosslinkable macromers and mixture of ionically and covalently crosslinkable macromers, that is the entire genera, while Exhibit 1 and Figures 1A to 1J show species of said genera. See Exhibit 1 and paragraphs 0039 and 0040 of US 2004/0138329 (applicants' published application). The underlying science does not extend the support from the species to the entire genus. In other words applicants' claims are broader than the support shown in the applications predating 8/1/1995. The effective filing date of the instant application remains August 1, 1995.

Double Patenting

- 2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 3. Claims 19 and 37 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 37-58 of U.S. Patent No. 5,334,640 (Reexamined). Although the conflicting claims are not identical, they are not patentably distinct from each other because the Reexamination Certificate discloses the species for applicants' genera. During reexamination claims 1-36 were cancelled and claims 37-58 were added. See Reexamination Certificate (4728th) of Desai et al. US 5,334,640. The priority date has no significance in the case of double patenting.

Application/Control Number: 10/743,687 Page 3

Art Unit: 1714

Claim Rejections - 35 USC § 102

4. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

- 5. Claim 19 is rejected under 35 U.S.C. 102(b or e) as being anticipated by Nisshinbo Industries, Inc. EP 0 555 980, Sumino et al. 4,791,061 or Kobayashi et al. 5,268,286.
- 6. Nisshinbo Industries discloses sodium alginate and sucrose in Example 1. Sumino et al. teach water soluble alginate in column 2, lines 25-29 and sodium, potassium and ammonium alginate in column 3, lines 11-14. Kobayashi et al. recite alginic acid derivatives in column 2, lines 33-38 and claim 1 and sodium alginate in claims 2-3. US 2004/0138329 states in paragraph 0102 that in the event that a substance such as alginate is used the resulting macromer will be both ionically crosslinkable and covalently crosslinkable. See also previous Office actions for explaining the rejections. Applicants' claims are not novel.
- 7. Claim 37 is rejected under 35 U.S.C. 102(b or e) as being anticipated by Nissibo Industries, Inc. EP 0 555 980, Sumino et al. 4,791,061, Feijen et al. 5,041,292 or Kobayashi et al. 5,268,286.
- 8. Feijen et al. display a proteinaceous component and a polysaccharide in claim 1.

 Protein is a covalently crosslinkable macromer and polysaccharides are ionically crosslinkable macromer. The other references have been discussed already previously.

 Applicants' claims are not novel.

Application/Control Number: 10/743,687 Page 4

Art Unit: 1714

9. The examiner's rejection is based on the third party submission of the reexamination procedure of U.S. Patent 5,334,640 to Desai et al., which is of record.

- 10. Claims 19 and 37 are rejected under 35 U.S.C. 102(e) as being anticipated by Desai et al. 5,550,78, Soon-Shiong et al. 5,705,270, Soon-Shiong et al. 5,705,848, Gunther et al. 5,736,595, Soon-Shiong et al. 5,837,747, Soon-Shiong et al. 5,846,530 or Mathiowitz et al. 5,985,354.
- 11. All references have been discussed in previous Office actions. Since the effective filing date of the instant application is 8/1/95, all the above references red on applicants' invention. Applicants' claims are not novel.

Conclusion

12. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1714

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter Szekely whose telephone number is (571) 272-1124. The examiner can normally be reached on 7:00 a.m.-5:30 p.m. Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vasu Jagannathan can be reached on (571) 272-1119. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Peter Szekely Primary Examiner Art Unit 1714

P.S. 3/2/06